Work

Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs23-po3-05-08

Authors: Sara Hurvitz, Anne Schott, Cynthia Ma, Rita Nanda, George Zahrah, Natasha Hunter, Antoinette Tan, Melinda Telli, Jesus Anampa Mesias, Rinath Jeselsohn, Pamela Munster, Eric Zhi, Elizabeth Duperret, Cecile Mather, Erika Hamilton, Hyo Han

Institutions: Fred Hutch Cancer Center, University of Michigan, Michigan Medicine, U-M Rogel Cancer Center, Washington University in St. Louis, University of Chicago, Levine Cancer Institute, Stanford University, Albert Einstein College of Medicine, Dana-Farber Cancer Institute, University of California, San Francisco, Arvinas (United States), Sarah Cannon, Moffitt Cancer Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396591089

Cites:

Cited by: 11

Related to: 10